LABIANA HEALTH, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.98 EUR | +2.76% |
|
+6.43% | +138.40% |
| Apr. 26 | Labiana Health, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2022 | Labiana Health, S.A. acquired 10.31% stake in Trichome Pharma. | CI |
| Sales 2024 * | 66M 71.91M | Sales 2025 * | 72M 78.45M | Capitalization | 20.48M 22.31M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | 1M 1.09M | EV / Sales 2024 * | 0.84 x |
| Net Debt 2024 * | 35M 38.13M | Net Debt 2025 * | 35M 38.13M | EV / Sales 2025 * | 0.77 x |
| P/E ratio 2024 * |
145
x | P/E ratio 2025 * |
14.9
x | Employees | 433 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 29.88% |
More Fundamentals
* Assessed data
More press releases
More news
| 1 day | +2.76% | ||
| 1 week | +6.43% | ||
| Current month | +10.37% | ||
| 1 month | +17.32% | ||
| 3 months | +92.26% | ||
| 6 months | +109.86% | ||
| Current year | +138.40% |
1 week
2.82
2.98
1 month
2.542.98
Current year
1.182.98
1 year
1.052.98
3 years
1.054.95
5 years
1.054.95
10 years
1.054.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
Miquel Pujolriu
DFI | Director of Finance/CFO | - | - |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Director/Board Member | - | - | |
| Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-16 | 2.98 | +2.76% | 1 295 |
| 24-07-15 | 2.9 | 0.00% | 875 |
| 24-07-12 | 2.9 | +2.11% | 7,645 |
| 24-07-11 | 2.84 | 0.00% | 0 |
| 24-07-10 | 2.84 | +1.43% | 1,941 |
Delayed Quote BME, July 16, 2024 at 06:31 am EDT
More quotes
Labiana Health SA is a Spain-based holding company involved in the pharmaceuticals sector. The Firm, through its subsidiaries, is engaged in the development, manufacturing and marketing of animal and human medicines. The Companyâs main activities are: Drug research and development (R&D), which includes galenic and analytical development; Drug manufacturing, which focuses on formulation development, formulation optimization, bacterial vaccine manufacturing, among others; Regulatory services, which carries out registration procedures for pharmaceutical products in world markets. The Company, through its subsidiaries, is present in Ecuador, Mexico, Serbia and Turkey.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.9
EUR
Average target price
2.4
EUR
Spread / Average Target
-17.24%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +138.40% | 22.35M | |
| -10.40% | 6.6B | |
| +35.00% | 3.99B | |
| +0.97% | 3.38B | |
| +21.45% | 1.76B | |
| -1.95% | 1.28B | |
| -39.28% | 1.01B | |
| -43.09% | 950M | |
| -19.34% | 843M | |
| -36.21% | 833M |
- Stock Market
- Equities
- LAB Stock
